FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women
Gisella Figlioli, Montserrat García‐Closas(Institute of Cancer Research), Marina Bermisheva(Russian Academy of Sciences), Ole Christian Lingjærde(Oslo University Hospital), Solveig Hofvind(Norwegian Institute of Public Health), Natalia Bogdanova(Medizinische Hochschule Hannover), Peter A. Fasching(Universitätsklinikum Erlangen), Melissa H. Cessna(Intermountain Healthcare), Jose E. Castelao(Servicio Gallego de Salud), Manuela Gago-Domínguez(University of Southern California), Thilo Dörk(Hannover Re (Germany)), Jonine D. Figueroa, Heiko Becher(Universität Hamburg), Britt Fritzman(Oslo University Hospital), Jürgen Geisler(Oslo University Hospital), Archie Campbell(Vanderbilt University), Gry Aarum Geitvik(Oslo University Hospital), Christoph Engel(University Hospital Leipzig), Kristine Kleivi Sahlberg(University of Oslo), Marinus J. Blok(Maastricht University), Mikael Eriksson(Herlev Hospital), Kamila Czene(Karolinska Institutet), Tone F. Bathen, Helle Kristine Skjerven(Vestre Viken Hospital Trust), Hege G. Russnes(Oslo University Hospital), Matthias W. Beckmann(Universitätsklinikum Erlangen), Thomas U. Ahearn(Harvard University), Peter Devilee(Leiden University), Marike Gabrielson(Karolinska Institutet), Amandine Billaud(IFOM), Sabine Behrens(German Cancer Research Center), Javier Benı́tez(Spanish National Cancer Research Centre), Thérese Sørlie(Norwegian Cancer Society), Elin Borgen(Oslo University Hospital), Gunhild M. Mælandsmo(Oslo University Hospital), Inger Torhild Gram(St. Elizabeth's Hospital), Nicola J. Camp(University of Utah), Karina Standahl Olsen(UiT The Arctic University of Norway), Bernardo Bonanni(European Institute of Oncology), Stephen J. Chanock(National Cancer Institute), Barbara Burwinkel(German Cancer Research Center), Natalia Antonenkova(N.N. Alexandrov National Cancer Centre), Anne‐Lise Børresen‐Dale(Oslo University Hospital), Øystein Garred(Oslo University Hospital), Anita Langerød(Norwegian Cancer Society), Bjørn Naume(Norwegian Cancer Society), Grethe I.G. Alnæs(Oslo University Hospital), Olav Engebråten(University of Oslo)
Cited by 14
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k